SCHEMBL13020094

SCHEMBL13020094

CCn1nc(Nc2cccc3ccccc23)c2c(N)ncnc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.53
▸ PRKDC P78527 2/20 0.53
▸ KDR P35968 3/20 0.48
▸ RET P07949 2/20 0.48
▸ EGFR P00533 2/20 0.46
▸ SRC P12931 10/20 0.45
▸ ABL1 P00519 6/20 0.45
▸ PRKD3 O94806 3/20 0.45
▸ PRKD1 Q15139 3/20 0.45
▸ PRKD2 Q9BZL6 3/20 0.45
▸ RIPK2 O43353 2/20 0.45
▸ FYN P06241 2/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ CSK P41240 2/20 0.45
▸ MAPK8 P45983 2/20 0.45
▸ CAMK2A Q9UQM7 2/20 0.45
▸ HCK P08631 2/20 0.45
▸ PRKACA P17612 1/20 0.45
▸ CSNK1A1 P48729 1/20 0.45
▸ CSNK1E P49674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3787263 0.82 PIK3CD (0.52) PIK3CDPRKDCKDRRETEGFR
SCHEMBL19359145 0.81 SRC (0.65) PIK3CDPRKDCKDRRETSRC
SCHEMBL30356540 0.81 SRC (0.65) PIK3CDPRKDCKDRRETSRC
SCHEMBL13019719 0.77 SRC (0.71) PIK3CDPRKDCKDRRETSRC
SCHEMBL13019932 0.76 PIK3CD (0.52) PIK3CDPRKDCKDRRETEGFR
SCHEMBL13020058 0.76 SRC (0.69) PIK3CDPRKDCKDRRETEGFR
SCHEMBL13019983 0.74 PIK3CD (0.50) PIK3CDPRKDCKDRRETEGFR
SCHEMBL13019940 0.74 PIK3CD (0.50) PIK3CDPRKDCKDRRETSRC
SCHEMBL13020098 0.70 PIK3CA (0.42) PIK3CDPRKDCKDRRETEGFR
SCHEMBL15826968 0.70 PIK3CD (0.73) PIK3CDPRKDCKDRRETEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B PIK3CD 2217/4885PRKDC 1498/4885KDR 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback